Related references
Note: Only part of the references are listed.Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Justine S. Paradis et al.
CLINICAL CANCER RESEARCH (2021)
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Hong Jiang et al.
GUT (2020)
A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic Screen
John C. Dawson et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer
Haisheng Zhang et al.
CANCER DISCOVERY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E. Gerber et al.
LUNG CANCER (2020)
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication
Hsin-Jung Wu et al.
ONCOGENE (2020)
SOX9: The master regulator of cell fate in breast cancer
Samir Jana et al.
BIOCHEMICAL PHARMACOLOGY (2020)
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
Marta Canel et al.
ELIFE (2020)
Cancer associated fibroblast FAK regulates malignant cell metabolism
Fevzi Demircioglu et al.
NATURE COMMUNICATIONS (2020)
Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells
Qi Ma et al.
CELL REPORTS (2020)
FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
Hongying Gao et al.
PROTEIN & CELL (2020)
Structural basis of Focal Adhesion Kinase activation on lipid membranes
Ivan Acebron et al.
EMBO JOURNAL (2020)
FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer
Sonia Zaghdoudi et al.
EMBO MOLECULAR MEDICINE (2020)
Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth
Tanguy Lechertier et al.
NATURE COMMUNICATIONS (2020)
A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK
Xiaodong Feng et al.
CANCER CELL (2019)
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
Johannes Popow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Maja J. A. de Jonge et al.
TARGETED ONCOLOGY (2019)
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
Gabriel Mak et al.
BRITISH JOURNAL OF CANCER (2019)
Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and-861
Ana-Rita Pedrosa et al.
CANCER RESEARCH (2019)
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Carlos J. Diaz Osterman et al.
ELIFE (2019)
FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer
Young-Ho Kim et al.
CANCERS (2019)
YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression
Huapeng Li et al.
CELL REPORTS (2019)
YAP and TAZ: a signalling hub of the tumour microenvironment
Francesca Zanconato et al.
NATURE REVIEWS CANCER (2019)
Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Guangming Chen et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
Ulrich A. Hirt et al.
ONCOGENESIS (2018)
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development
Rayan Naser et al.
CANCERS (2018)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera et al.
FRONTIERS IN ONCOLOGY (2018)
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Francesca Zanconato et al.
NATURE MEDICINE (2018)
Hippo signaling dysfunction induces cancer cell addiction to YAP
Han Han et al.
ONCOGENE (2018)
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Philipp M. Cromm et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
Kyaw Lwin Aung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors
Ernst Lengyel et al.
TRENDS IN CANCER (2018)
Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions
Jing Tang et al.
CELL CHEMICAL BIOLOGY (2018)
A Phosphosite within the SH2 Domain of Lck Regulates Its Activation by CD45
Adam H. Courtney et al.
MOLECULAR CELL (2017)
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state
Mohammad Fallahi-Sichani et al.
MOLECULAR SYSTEMS BIOLOGY (2017)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
A subcellular map of the human proteome
Peter J. Thul et al.
SCIENCE (2017)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks
Bryan Serrels et al.
SCIENCE SIGNALING (2017)
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
Venessa T. Chin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
Jennifer Ducie et al.
NATURE COMMUNICATIONS (2017)
LFA-1 activates focal adhesion kinases FAK1/PYK2 to generate LAT-GRB2-SKAP1 complexes that terminate T-cell conjugate formation
Monika Raab et al.
NATURE COMMUNICATIONS (2017)
Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer
Joe Ryan Delaney et al.
NATURE COMMUNICATIONS (2017)
Inhibition of FAK kinase activity preferentially targets cancer stem cells
Vihren N. Kolev et al.
ONCOTARGET (2017)
Ambra1 spatially regulates Src activity and Src/FAK-mediated cancer cell invasion via trafficking networks
Christina Schoenherr et al.
ELIFE (2017)
IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks
Bryan Serrels et al.
SCIENCE SIGNALING (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer
Yu Kang et al.
CLINICAL CANCER RESEARCH (2016)
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
Min Hwan Kim et al.
EMBO JOURNAL (2016)
Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis
J. Zhang et al.
ONCOGENE (2016)
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
J. C. Soria et al.
ANNALS OF ONCOLOGY (2016)
A systematic comparison of copy number alterations in four types of female cancer
Fatemeh Kaveh et al.
BMC CANCER (2016)
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
Toshio Shimizu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
Josephine Walton et al.
CANCER RESEARCH (2016)
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Ke-Jing Tang et al.
CLINICAL CANCER RESEARCH (2016)
Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer
Heath D. Skinner et al.
CLINICAL CANCER RESEARCH (2016)
YAP/TAZ as therapeutic targets in cancer
Francesca Zanconato et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Integrin signalling regulates YAP and TAZ to control skin homeostasis
Ahmed Elbediwy et al.
DEVELOPMENT (2016)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
Hanane Laklai et al.
NATURE MEDICINE (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Ovarian cancer
Ursula A. Matulonis et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
FAK to the Rescue: Activated Stroma Promotes a Safe Haven'' for BRAF-Mutant Melanoma Cells by Inducing FAK Signaling
Margaret C. Frame et al.
CANCER CELL (2015)
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
Eishu Hirata et al.
CANCER CELL (2015)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Suzanne F. Jones et al.
INVESTIGATIONAL NEW DRUGS (2015)
Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway
Nam-Gyun Kim et al.
JOURNAL OF CELL BIOLOGY (2015)
Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly
Edward R. Horton et al.
NATURE CELL BIOLOGY (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
FAK signaling in human cancer as a target for therapeutics
Brian Y. Lee et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Focal Adhesion Kinase and Wnt Signaling Regulate Human Ductal Carcinoma In Situ Stem Cell Activity and Response to Radiotherapy
Kathryn E. Williams et al.
STEM CELLS (2015)
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
Anil Belur Nagaraj et al.
ONCOTARGET (2015)
FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β
Chenxi Gao et al.
ELIFE (2015)
Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement
Nicole M. Chapman et al.
IMMUNOLOGIC RESEARCH (2014)
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function
Christine Jean et al.
JOURNAL OF CELL BIOLOGY (2014)
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Bernardo Tavora et al.
NATURE (2014)
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis
Silvia Batista et al.
NATURE COMMUNICATIONS (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.
Manish R. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+T cell activation
Andrew J. Wiemer et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Distinct FAK Activities Determine Progenitor and Mammary Stem Cell Characteristics
Ming Luo et al.
CANCER RESEARCH (2013)
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression
Kristy K. Ward et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Focal Adhesion Kinase Negatively Regulates Lck Function Downstream of the T Cell Antigen Receptor
Nicole M. Chapman et al.
JOURNAL OF IMMUNOLOGY (2013)
Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer
Yu Kang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP
Yi Liu-Chittenden et al.
GENES & DEVELOPMENT (2012)
Compensatory Function of Pyk2 Protein in the Promotion of Focal Adhesion Kinase (FAK)-null Mammary Cancer Stem Cell Tumorigenicity and Metastatic Activity
Huaping Fan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
Jayme B. Stokes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Focal Adhesion Kinase Is Required for Intestinal Regeneration and Tumorigenesis Downstream of Wnt/c-Myc Signaling
Gabrielle H. Ashton et al.
DEVELOPMENTAL CELL (2010)
Endothelial FAK is required for tumour angiogenesis
Bernardo Tavora et al.
EMBO MOLECULAR MEDICINE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
Llen L. Goode et al.
NATURE GENETICS (2010)
The FERM domain: organizing the structure and function of FAK
Margaret C. Frame et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Identification of Candidate Growth Promoting Genes in Ovarian Cancer through Integrated Copy Number and Expression Analysis
Manasa Ramakrishna et al.
PLOS ONE (2010)
Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer
Kylie L. Gorringe et al.
PLOS ONE (2010)
Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2
James Lulo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Mammary Epithelial-Specific Ablation of the Focal Adhesion Kinase Suppresses Mammary Tumorigenesis by Affecting Mammary Cancer Stem/Progenitor Cells
Ming Luo et al.
CANCER RESEARCH (2009)
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model
Jill K. Slack-Davis et al.
MOLECULAR CANCER THERAPEUTICS (2009)
FAK Phosphorylation by ERK Primes Ras-Induced Tyrosine Dephosphorylation of FAK Mediated by PIN1 and PTP-PEST
Yanhua Zheng et al.
MOLECULAR CELL (2009)
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271
Walter Gregory Roberts et al.
CANCER RESEARCH (2008)
The challenge of selecting protein kinase assays for lead discovery optimization
Haiching Ma et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK
Sara M. Weis et al.
JOURNAL OF CELL BIOLOGY (2008)
PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility
Yang Lim et al.
JOURNAL OF CELL BIOLOGY (2008)
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation
Ssang-Taek Lim et al.
MOLECULAR CELL (2008)
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression
Hicham Lahlou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex
Bryan Serrels et al.
NATURE CELL BIOLOGY (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Structural basis for the autoinhibition of focal adhesion kinase
Daniel Lietha et al.
CELL (2007)
Cellular characterization of a novel focal adhesion kinase inhibitor
Jill K. Slack-Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression
GW McLean et al.
GENES & DEVELOPMENT (2004)
T cell fitness determined by signal strength
AV Gett et al.
NATURE IMMUNOLOGY (2003)
Share Paper
